Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Irfan Cicin (), Ergun Oksuz (), Nuri Karadurmus (), Simten Malhan (), Mahmut Gumus (), Ulku Yilmaz (), Levent Cansever (), Halit Cinarka (), Erdogan Cetinkaya (), Murat Kiyik () and Ahmet Ozet ()
Additional contact information
Irfan Cicin: Trakya University
Ergun Oksuz: Baskent University
Nuri Karadurmus: Gulhane Training and Research Hospital
Simten Malhan: Baskent University
Mahmut Gumus: Istanbul Medeniyet University
Ulku Yilmaz: University of Health Sciences, Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital
Levent Cansever: University Of Health Sciences
Halit Cinarka: University Of Health Sciences
Erdogan Cetinkaya: University Of Health Sciences
Murat Kiyik: University Of Health Sciences
Ahmet Ozet: Gazi University

Health Economics Review, 2021, vol. 11, issue 1, 1-12

Abstract: Abstract Background This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. Results Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Conclusions Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments.

Keywords: Lung cancer; Practice patterns; Cost of illness; Direct costs; Indirect costs; Economic burden; Turkey (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1186/s13561-021-00322-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:11:y:2021:i:1:d:10.1186_s13561-021-00322-2

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-021-00322-2

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().